drugset / Trial / NCT02292225
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.
Timeline
- Start
- 2015-02
- Primary completion
- 2016-11
- Completion
- 2016-11
Outcome
Outcome not reported
Stopped: “The scope of the program has been reduced to focus resources on studies which can potentially enable the registration of duvelisib.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | 5 mg | Oral |
| Subject | Duvelisib | Small molecule | 25 mg | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | — |